CO2021012579A2 - Compuestos útiles en la terapia del vih - Google Patents

Compuestos útiles en la terapia del vih

Info

Publication number
CO2021012579A2
CO2021012579A2 CONC2021/0012579A CO2021012579A CO2021012579A2 CO 2021012579 A2 CO2021012579 A2 CO 2021012579A2 CO 2021012579 A CO2021012579 A CO 2021012579A CO 2021012579 A2 CO2021012579 A2 CO 2021012579A2
Authority
CO
Colombia
Prior art keywords
useful compounds
hiv therapy
hiv
compounds
therapy
Prior art date
Application number
CONC2021/0012579A
Other languages
English (en)
Inventor
Emile Johann Velthuisen
David Temelkoff
La Rosa Martha Alicia De
John F Miller
B Narasimhulu Naidu
Vicente Samano
Original Assignee
Glaxosmithkline Ip No 2 Ltd
Viiv Healthcare Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip No 2 Ltd, Viiv Healthcare Co filed Critical Glaxosmithkline Ip No 2 Ltd
Publication of CO2021012579A2 publication Critical patent/CO2021012579A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/173—Purine radicals with 2-deoxyribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere a compuestos de fórmula (i), sales de los mismos, compuestos farmacéuticos de los mismos, así como a métodos de tratamiento y prevención de VIH en sujetos.
CONC2021/0012579A 2019-03-06 2021-09-24 Compuestos útiles en la terapia del vih CO2021012579A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962814316P 2019-03-06 2019-03-06
PCT/IB2020/051878 WO2020178767A1 (en) 2019-03-06 2020-03-04 Compounds useful in hiv therapy

Publications (1)

Publication Number Publication Date
CO2021012579A2 true CO2021012579A2 (es) 2021-10-20

Family

ID=69845479

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0012579A CO2021012579A2 (es) 2019-03-06 2021-09-24 Compuestos útiles en la terapia del vih

Country Status (21)

Country Link
US (2) US20230174534A1 (es)
EP (1) EP3934760A1 (es)
JP (1) JP2022525013A (es)
KR (1) KR20210136052A (es)
CN (1) CN113811360A (es)
AR (1) AR118240A1 (es)
AU (1) AU2020231934B2 (es)
BR (1) BR112021017604A2 (es)
CA (1) CA3132112A1 (es)
CL (1) CL2021002309A1 (es)
CO (1) CO2021012579A2 (es)
CR (1) CR20210460A (es)
EA (1) EA202192433A1 (es)
IL (1) IL285894A (es)
MA (1) MA55200A (es)
MX (1) MX2021010700A (es)
PE (1) PE20212089A1 (es)
SG (1) SG11202109253SA (es)
TW (1) TW202102233A (es)
WO (1) WO2020178767A1 (es)
ZA (1) ZA202106096B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202135815A (zh) 2019-12-09 2021-10-01 美商 Ｖｉｉｖ 醫療保健公司 醫藥組合物
AU2021237718B2 (en) * 2020-03-20 2023-09-21 Gilead Sciences, Inc. Prodrugs of 4'-C-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
CN116370479B (zh) * 2020-12-30 2024-02-13 南方科技大学 化合物atv014在制备用于治疗新冠病毒感染的产品中的用途
TW202237146A (zh) * 2021-01-25 2022-10-01 美商布里生物科學股份有限公司 使用腺苷衍生物及衣殼抑制劑之hiv組合療法
JP2024507550A (ja) * 2021-02-23 2024-02-20 ヴィーブ、ヘルスケア、カンパニー Ｈｉｖ療法に有用な化合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB427857A (en) 1934-08-02 1935-05-01 Newsum Sons & Company Ltd H A new or improved system of construction for skeleton structures, particularly vehicle body frames and door frames
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
NZ528270A (en) 2001-03-19 2005-10-28 Ono Pharmaceutical Co Drugs containing triazaspiro[5.5]undecane derivatives as the active ingredient
CA2502109C (en) 2004-03-24 2010-02-23 Yamasa Corporation 4'-c-substituted-2-haloadenosine derivative
WO2015143712A1 (en) * 2014-03-28 2015-10-01 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors
EP3203995A4 (en) * 2014-10-09 2019-05-15 Board of Regents of the University of Nebraska COMPOSITIONS AND METHODS FOR DELIVERY OF THERAPEUTIC AGENTS
EP3212597A1 (en) * 2014-10-31 2017-09-06 Sandoz AG Improved fluorination process
CA2998646C (en) * 2015-09-23 2021-05-18 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors and preparations thereof
JOP20170038B1 (ar) * 2016-02-12 2021-08-17 Merck Sharp & Dohme مركبات للاستخدام لعلاج عدوى بفيروس hiv والوقاية منه
EP3529254B1 (en) * 2016-11-03 2023-02-22 Laurence I. Wu Prodrugs of clofarabine
US20200407393A1 (en) * 2018-03-07 2020-12-31 Glaxosmithkline Intellectual Property (No. 2) Limited Medical Use

Also Published As

Publication number Publication date
EA202192433A1 (ru) 2021-12-28
EP3934760A1 (en) 2022-01-12
CA3132112A1 (en) 2020-09-10
US20230174534A1 (en) 2023-06-08
WO2020178767A1 (en) 2020-09-10
AU2020231934A8 (en) 2022-03-24
US20220411425A1 (en) 2022-12-29
AU2020231934A1 (en) 2021-09-23
AR118240A1 (es) 2021-09-22
IL285894A (en) 2021-10-31
CN113811360A (zh) 2021-12-17
MA55200A (fr) 2022-01-12
CL2021002309A1 (es) 2022-09-20
AU2020231934B2 (en) 2023-04-20
MX2021010700A (es) 2021-10-01
TW202102233A (zh) 2021-01-16
KR20210136052A (ko) 2021-11-16
SG11202109253SA (en) 2021-09-29
PE20212089A1 (es) 2021-11-04
ZA202106096B (en) 2023-03-29
JP2022525013A (ja) 2022-05-11
BR112021017604A2 (pt) 2021-11-16
CR20210460A (es) 2022-02-03

Similar Documents

Publication Publication Date Title
UY37710A (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana
CO2021012579A2 (es) Compuestos útiles en la terapia del vih
CL2020000501A1 (es) Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp1) y usos de los mismos.
CL2019002204A1 (es) Compuestos inhibidores del vih.
UY36648A (es) Inhibidores de la replicación del virus de inmunodeficiencia humana
NZ735575A (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
CU20150096A7 (es) Compuestos de amida y composición farmacéutica para el tratamiento de vih
ECSP12012106A (es) Terapia antiviral
EA201791019A1 (ru) Полициклические карбамоилпиридоновые соединения и их фармацевтическое применение
CL2020000886A1 (es) Derivados de 1-benzil-2-imino-4-fenil-5-oxoimidazolidina como inhibidores de la proteasa del vih.
UY36371A (es) Compuestos de indolcarboxamida inhibidores de quinasas tipo btk y tipo tec
EA201791515A1 (ru) Соединения пиразина для лечения инфекционных заболеваний
UY36649A (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana
UY36212A (es) Moduladores de receptores tipo toll para el tratamiento del vih
CO6781497A2 (es) Tratamiento para la lipodistrofia
MA39995B1 (fr) Composés destinés à traiter l'amyotrophie spinale
CL2021001388A1 (es) Compuestos útiles en la terapia para el vih
EA201590358A1 (ru) Ингибиторы репликации вируса иммунодефицита человека
EA201690687A1 (ru) Ингибиторы репликации вируса иммунодефицита
CL2021000329A1 (es) Compuestos útiles en terapia del vih
DOP2018000035A (es) Derivados del ácido 5-(n-bencil-tetrahidroisoquinolin-6-il)-piridin-3-il acético como inhibidores de la replicación del virus de la inmunodeficiencia humana
DOP2021000062A (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana.
EA201790495A1 (ru) Фармацевтические композиции длительного действия
EA201890906A1 (ru) ПРОИЗВОДНЫЕ ХИНОКСАЛИНА И ПИРИДОПИРАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ
CL2017002498A1 (es) Piridopirimidinonas y su uso como modulares del receptor nmda